Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARTV 
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ARTV (1-star) is a SELL. SELL since 2 days. Simulated Profits (-0.84%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.4
1 Year Target Price $15.4
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.02% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.89M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.47 - 17.31 | Updated Date 09/17/2025 |
52 Weeks Range 1.47 - 17.31 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.57% | Return on Equity (TTM) -86.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -71251945 | Price to Sales(TTM) 214.51 |
Enterprise Value -71251945 | Price to Sales(TTM) 214.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24425800 | Shares Floating 5381728 |
Shares Outstanding 24425800 | Shares Floating 5381728 | ||
Percent Insiders 19.88 | Percent Institutions 75.94 |
Upturn AI SWOT
Artiva Biotherapeutics, Inc. Common Stock
Company Overview
History and Background
Artiva Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing and commercializing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat cancer. Founded in 2019, Artiva leverages its AlloNKu00ae platform to advance a pipeline of NK cell therapies for hematologic malignancies and solid tumors.
Core Business Areas
- AlloNKu00ae Cell Therapy Development: Artiva's core business is the development of AlloNKu00ae cell therapies. These therapies are derived from umbilical cord blood and engineered for enhanced cytotoxicity and persistence.
Leadership and Structure
The leadership team includes Peter Flynn, PhD as CEO and Fred Aslan, MD as CFO. The organizational structure involves research, development, clinical operations, and commercial strategy teams.
Top Products and Market Share
Key Offerings
- ATRA-19: An ADCC enhancer and binder of rituximab or obinutuzumab to increase effectiveness in treating B-cell lymphomas. Competitors include other ADCC enhancers and alternative lymphoma treatments.
- AB-101: An allogeneic, off-the-shelf NK cell therapy targeting hematologic malignancies. AB-101 is in clinical trials for relapsed or refractory B-cell lymphomas. Competitors include autologous CAR-T cell therapies and other allogeneic NK cell therapies.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by increasing demand for novel cancer treatments. The allogeneic NK cell therapy segment is emerging with potential advantages over autologous approaches.
Positioning
Artiva is positioned as a leader in the allogeneic NK cell therapy space, with a focus on developing off-the-shelf therapies for a wide range of cancers.
Total Addressable Market (TAM)
The TAM for cell therapies is expected to reach tens of billions of dollars in the coming years. Artiva aims to capture a significant share by developing accessible and effective allogeneic NK cell therapies.
Upturn SWOT Analysis
Strengths
- Proprietary AlloNKu00ae platform
- Strong leadership team
- Advancing clinical pipeline
- Potential for off-the-shelf scalability
- Strategic partnerships
Weaknesses
- Early-stage clinical development
- Reliance on clinical trial success
- High research and development costs
- Limited commercial infrastructure
Opportunities
- Expanding into new cancer indications
- Partnering with larger pharmaceutical companies
- Developing next-generation NK cell therapies
- Addressing unmet medical needs in oncology
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- NKT Therapeutics (NKX)
- Fate Therapeutics (FATE)
- Gamida Cell (GMDA)
Competitive Landscape
Artiva has a competitive advantage in its AlloNKu00ae platform and strategic collaborations. However, it faces competition from larger, more established cell therapy companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the expansion of the clinical pipeline and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on the perceived potential of Artiva's AlloNKu00ae platform.
Recent Initiatives: Recent initiatives include advancing clinical trials for AB-101 and ATRA-19 and expanding manufacturing capabilities.
Summary
Artiva Biotherapeutics is a promising, albeit early-stage, player in the allogeneic NK cell therapy market. Its AlloNKu00ae platform holds significant potential, but its success is contingent on positive clinical trial outcomes. Financial health is currently reliant on continued fundraising. Regulatory hurdles and competition also pose challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.artivabio.com |
Full time employees 105 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.